Passionate about neuroscience? 🧠
We’re recruiting a PhD student to join INSPECT-DLB - improving the diagnosis of dementia with Lewy bodies.
Work at QUB with @ecebayram.bsky.social, Dr Claire McEvoy, me & team on this @lewybodysociety.bsky.social-funded project.
🔗 tinyurl.com/yck7466a
Congratulations Jon and colleagues!
We are counting down for #AAIC25 and to catch up with our #LBDPIA members in person 😍 As we wait patiently, we prepared a webpage for you to find us, check out our work and join our team:
sites.google.com/view/lbdpia-...
I’d really like to applaud your almost single-handed attempts to reintroduce “wick” into the modern lexicon. When one of your characters said it on a R4 play I heard it absolutely made my day
🎓 Are you an early-career researcher in #LewyBodyDementia? Join us at Lewy Connect, hosted by LBDA at #AAIC2025!
🗓️ July 29, 6–8pm
📍 InterContinental Toronto Centre
🔗 Network, meet LBD leaders, build your career!
RSVP now—space is limited! 👇
doodle.com/sign-up-shee...
There’s a lot of DLB research happening, but what are we actually asking people with DLB and their care partners? Which perspectives are we missing?
@qubelfastofficial.bsky.social PhD candidate Paula Sinéad Donnelly leads this insightful scoping review👇
alzres.biomedcentral.com/articles/10....
Last week @qubelfastofficial.bsky.social we were delighted to host Dr Yuto Satake from Osaka University and @ucl.ac.uk to discuss his work on AD & DLB biomarkers, very late onset psychosis and tackling loneliness with SoTa the robot. Come back soon Yuto!
We were joined today by attendees from FORTY-SIX countries!
🇦🇫 🇦🇽 🇩🇿 🇦🇴 🇦🇷 🇦🇿 🇧🇷 🇧🇳 🇧🇫 🇨🇦 🇨🇱 🇨🇳 🇨🇴 🇨🇿 🇪🇬 🇬🇪 🇩🇪 🇬🇭 🇬🇷 🇭🇰 🇮🇳 🇮🇩 🇮🇪 🇰🇪 🇲🇹 🇲🇺 🇲🇲 🇳🇬 🇵🇰 🇵🇪 🇵🇭 🇸🇦 🇸🇬 🇿🇦 🇪🇸 🇱🇰 🇸🇪 🇹🇼 🇹🇭 🇹🇹 🇹🇳 🇹🇷 🇬🇧 🇺🇸 🇻🇪 🇻🇳
📢📢 @istaart.bsky.social #DemenciaConCuerposDeLewy Seminario de Casos Clínicos en español tendrá lugar el 13 de mayo,10am US CT📢📢 #LBDPIA vicepresidente
@frodriguezporcel.bsky.social moderará con oradores fabulosos Ceci Fernandez,Ruth Agnew&Fernando Garcia
Regístrate!
alz-org.zoom.us/webinar/regi...
screenshot of a zoom webinar with five doctors speaking
Fantastic to host today's @istaart.bsky.social #LBDPIA Clinical Case Review webinar, with presentations from Dra. Cecilia Fernández & Drs Agnew, Garcia & Barton from @belfasttrust.bsky.social.
Tomorrow's webinar will discuss the same cases in Spanish - register here istaart.alz.org/events/item/...
Genial haber sido anfitrión del seminario web de Revisión de Casos Clínicos @istaart.bsky.social #LBDPIA de hoy con Dra. Cecilia Fernández y Drs. Agnew, Garcia y Barton de @belfasttrust.bsky.social.
Regístrate aquí para nuestro seminario web en español mañana: istaart.alz.org/events/item/...
News article with this passage highlighted: "who asked not to be identified because she has always wanted to be an anonymous source"
Don't let anyone tell you that you can't live your dreams
Perhaps the larger problem is that when you establish memory clinics galore that many parts of the system don’t adequate look beyond memory
I don’t know to be honest. You would assume that, in the most part, they’re doing neuro exams either - so there would be a knock on effect on sensitivity. I do think that quality of care is too often conflated with diagnostic rates - and it is in the former that the MDT comes into its own
Could you expand on what you mean by “less skilled clinical staff”?
I do think “sketchy” is a bit harsh. Every specialty & service has its blind spots. Fluctuations tricky at best of times & RBD requires bed partner informant for recognition. in routine practice - especially in older populations - there is no shortage of comorbidities& complicating factors
Parkinsonism not necessarily late-emerging. And DaTScans not 100% necessary in all cases but crucial in some. The failure to detect Parkinsonism or have an abnormal DaT can be the difference between an AD diagnosis and a DLB one.
Patients with DLB are certainly not all referred to neuro - when you look for the symptoms in “memory clinic” populations, they’re there…
It’s because psychiatry led services are much less likely to do a neuro exam and therefore more likely to miss Parkinsonism. Anecdotally may be less likely to detect fluctuations or RBD. Access to DaTScans varies a lot geographically and so do clinicians’ diagnostic thresholds
ISTAART is on Bluesky! Follow us as we discuss the latest in research and treatment and make connections to grow the global dementia science community.
This is a flyer for AAIC25 in Toronto. "Put a spotlight on your research" - abstract and session proposals due Jan 27th at alz.org/AAIC2025
#AAIC25 is Canada-bound 🇨🇦
Abstract and session proposals can now be submitted at aaic.alz.org
@kaanthanj.bsky.social the profile pic 😂😂😂
@carlaabdelnour.bsky.social bienvenida Carla!
@rikossenkoppele.bsky.social welcome Rik!
“Well, here we all are now, all the lads”.
EU medicines agency has revised its initial verdict on lecanemab in (non ApoE4 homozygous) Alzheimer’s disease - recommending authorisation to EU bodies
www.ema.europa.eu/en/news/leqe...
Bill Murray
AFC Bournemouth's Philip Billing
Buffalo Bills Logo
A summary of EPIC training.
"This must be the place", LP cover by Talking heads, depicting hands elbows and knees on a blue background